Skip to main content
Case Study

Assessment of MYC-driven progression of small cell lung cancer


Lung cancer is the leading cause of cancer death worldwide with Small Cell Lung Cancer (SCLC), an aggressive form with a typical survival rate of 10-12 months, accounting for roughly 14% of all lung cancers. Poor prognostic factors for this type of lung cancer coupled with the fact that the chemotherapy regimen has not changed substantially in 40 years highlight the urgent need to develop new therapeutic approaches to treating SCLC.

Read this case study to learn how Dr. Trudy Oliver and colleagues at the Huntsman Cancer Research Center in Salt Lake City, Utah (USA) used a Genetically Engineered Mouse Model (GEMM) and microCT imaging using the Quantum system to study and quantify tumor growth, progression, and evaluate treatment approaches in MYC-driven SCLC tumors.

For research use only. Not for use in diagnostic procedures. 

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Assessment of MYC-driven progression of small cell lung cancer

Download Case Study